Prostate-specific membrane antigen (PSMA) as a potential target for molecular imaging and treatment in bone and soft tissue sarcomas

Bone and soft tissue sarcomas are a group of rare malignant tumours with major histological and anatomical varieties. In a metastatic setting, sarcomas have a poor prognosis due to limited response rates to chemotherapy. Radioligand therapy targeting prostate-specific membrane antigen (PSMA) may offer a new perspective. PSMA is a type II transmembrane glycoprotein which is present in all prostatic tissue and overexpressed in prostate cancer. Despite the name, PSMA is not prostate-specific. PSMA expression is also found in a multitude of non-prostatic diseases including a subgroup of sarcomas, mostly in its neovascular endothelial cells. On PET/CT imaging, multiple sarcomas have also shown intense PSMA-tracer accumulation. PSMA expression and PSMA-tracer uptake seem to be highest in patients with aggressive and advanced sarcomas, who are also in highest need of new therapeutic options. Although these results provide a good rationale for the future use of PSMA-targeted radioligand therapy in a selection of sarcoma patients, more research is needed to gain insight into optimal patient selection methods, PSMA-targeting antibodies and tracers, administered doses of radioligand therapy, and their efficacy and tolerability. In this review, mRNA expression of the FOLH1 gene which encodes PSMA, PSMA immunohistochemistry, PSMA-targeted imaging and PSMA-targeted therapy in sarcomas will be discussed.

[1]  P. Castro,et al.  Schwannoma: A rare cause of false-positive 68Ga-PSMA PET/CT uptake in the evaluation of metastatic prostate cancer , 2021, Urology case reports.

[2]  M. Sungur,et al.  STAT3, VEGF, and PSMA Expression Patterns in Malignant Peripheral Nerve Sheath Tumors, Malignant Melanomas, and Glioblastomas: Does Staining Percentage and Intensity Have an Effect on Survival? , 2022, Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer.

[3]  Steffie M. B. Peters,et al.  89Zr-labeled PSMA ligands for pharmacokinetic PET imaging and dosimetry of PSMA-617 and PSMA-I&T: a preclinical evaluation and first in man , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  S. Usmani,et al.  Prostate-Specific Membrane Antigen Expression in Metastatic Angiosarcoma Detected on 18F-PMSA PET/CT: A New Potential Prognostic Marker. , 2021, Clinical nuclear medicine.

[5]  H. Moch,et al.  What’s behind 68Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  C. Gündoğan,et al.  Is 68Ga-Prostate-Specific Membrane Antigen PET/CT Superior than 18F-FDG PET/CT for Evaluation of Metastatic Osteosarcoma? , 2020, Clinical nuclear medicine.

[7]  W. Oyen,et al.  Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  M. Yadav,et al.  177Lu-/68Ga-PSMA Theranostics in Recurrent Glioblastoma Multiforme: Proof of Concept. , 2020, Clinical nuclear medicine.

[9]  C. Buchpiguel,et al.  Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings , 2020, Cancer Imaging.

[10]  L. Królicki,et al.  Tumor uptake in glioblastoma multiforme after IV injection of [177Lu]Lu-PSMA-617 , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  A. Agrawal,et al.  Incidental Detection of Pleomorphic Sarcoma on 68Ga-PSMA PET/CT in a Patient With Prostate Cancer. , 2020, Clinical nuclear medicine.

[12]  A. Maes,et al.  Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving 225Ac-PSMA-617 Radioligand Therapy , 2020, The Journal of Nuclear Medicine.

[13]  J. Wunder,et al.  Individualizing Follow-Up Strategies in High-Grade Soft Tissue Sarcoma with Flexible Parametric Competing Risk Regression Models , 2019, Cancers.

[14]  S. Inanır,et al.  68Ga-PSMA PET/CT in Giant Retroperitoneal Liposarcoma. , 2019, Clinical nuclear medicine.

[15]  W. Oyen,et al.  EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT) , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  R. Boellaard,et al.  Healthy Tissue Uptake of 68Ga-Prostate-Specific Membrane Antigen, 18F-DCFPyL, 18F-Fluoromethylcholine, and 18F-Dihydrotestosterone , 2019, The Journal of Nuclear Medicine.

[17]  U. Lützen,et al.  Experimental 177Lu-PSMA-617 radioligand therapy in a patient with extended metastasized leiomyosarcoma , 2019, Nuklearmedizin.

[18]  P. Flamen,et al.  Incidental Detection of a Radiation-Induced Soft-Tissue Sarcoma on 68Ga-PSMA PET/CT in a Patient Previously Treated for Prostate Cancer. , 2019, Clinical nuclear medicine.

[19]  M. Sydes,et al.  Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort , 2019, European journal of cancer.

[20]  S. Probst,et al.  Splenic Hemangioma as a Potential Pitfall on PSMA-Targeted 18F-DCFPyL PET/CT. , 2019, Clinical nuclear medicine.

[21]  A. Afaq,et al.  68Ga-Prostate-Specific Membrane Antigen PET/CT: Incidental Finding of a Liposarcoma. , 2019, Clinical nuclear medicine.

[22]  Rajender Kumar,et al.  68Ga-PSMA-HBED-CC PET/CT and 18F-FDG PET/CT in Ewing Sarcoma. , 2019, Clinical nuclear medicine.

[23]  Rajender Kumar,et al.  Incidental Detection of Tracer Avidity in Liposarcoma on 68Ga-Labeled Prostate-Specific Membrane Antigen PET/CT. , 2018, Clinical nuclear medicine.

[24]  H. Hieronymus,et al.  Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors , 2018, The Journal of experimental medicine.

[25]  A. Sasikumar,et al.  68Ga-PSMA PET/CT in Osteosarcoma in Fibrous Dysplasia. , 2017, Clinical nuclear medicine.

[26]  M. Vendelbo,et al.  Subcutaneous Lobular Capillary Hemangioma on 68Ga-PSMA PET/CT. , 2017, Clinical nuclear medicine.

[27]  K. Rahbar,et al.  Expression of PSMA in tumor neovasculature of high grade sarcomas including synovial sarcoma, rhabdomyosarcoma, undifferentiated sarcoma and MPNST , 2016, Oncotarget.

[28]  P. Thomas,et al.  Prostate-Specific Membrane Antigen PET/CT Findings for Hepatic Hemangioma. , 2016, Clinical nuclear medicine.

[29]  G. Schembri,et al.  Schwannoma Showing Avid Uptake on 68Ga-PSMA-HBED-CC PET/CT. , 2016, Clinical nuclear medicine.

[30]  P. Dileo,et al.  What is the role of routine follow-up for localised limb soft tissue sarcomas? A retrospective analysis of 174 patients , 2014, British Journal of Cancer.

[31]  A. Okawa,et al.  How Long Should We Follow Patients With Soft Tissue Sarcomas? , 2014, Clinical orthopaedics and related research.

[32]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[33]  C. Stiller,et al.  Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project. , 2013, European journal of cancer.

[34]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[35]  Chao Zeng,et al.  Prostate-specific membrane antigen: a new potential prognostic marker of osteosarcoma , 2012, Medical Oncology.

[36]  Colin N. Dewey,et al.  RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.

[37]  A. Chinnaiyan,et al.  Nuclear versus Cytoplasmic Localization of Filamin A in Prostate Cancer: Immunohistochemical Correlation with Metastases , 2009, Clinical Cancer Research.

[38]  Sam S. Chang Overview of prostate-specific membrane antigen. , 2004, Reviews in urology.

[39]  V. Reuter,et al.  Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. , 1999, Cancer research.

[40]  M. van Glabbeke,et al.  Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  N. Nowak,et al.  Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene. , 1998, Biochimica et biophysica acta.